(Q43152517)

14 November 2017

title

Use of the chloride channel activator lubiprostone for constipation in adults with cystic fibrosis: a case series (English)

1 reference

14 November 2017

0 references

1 reference

Catherine E O'Brien

1

1 reference

14 November 2017

Paula J Anderson

series ordinal

2

1 reference

14 November 2017

Cindy D Stowe

series ordinal

3

1 reference

14 November 2017

language of work or name

English

0 references

publication date

23 February 2010

1 reference

Annals of Pharmacotherapy

14 November 2017

published in

1 reference

14 November 2017

volume

44

1 reference

14 November 2017

issue

3

1 reference

14 November 2017

page(s)

577-581

1 reference

Cystic Fibrosis Adult Care

14 November 2017

cites work

1 reference

Constipation in pediatric cystic fibrosis patients: an underestimated medical condition.

21 January 2018

1 reference

Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS.

21 January 2018

1 reference

Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers.

21 January 2018

1 reference

Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator

21 January 2018

1 reference

Lubiprostone stimulates duodenal bicarbonate secretion in rats

21 January 2018

1 reference

Chloride transporting capability of Calu-3 epithelia following persistent knockdown of the cystic fibrosis transmembrane conductance regulator, CFTR.

21 January 2018

1 reference

Stimulation of mucosal secretion by lubiprostone (SPI-0211) in guinea pig small intestine and colon.

21 January 2018

1 reference

Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice.

21 January 2018

1 reference

Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation

21 January 2018

1 reference

Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.

21 January 2018

1 reference

Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

21 January 2018

1 reference

Single-dose lubiprostone along with split-dose PEG solution without dietary restrictions for bowel cleansing prior to colonoscopy: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1M642

1 reference

14 November 2017

1 reference